Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834683 | 0.83 | ALB (0.59) | ALBMEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL6833124 | 0.77 | ALB (0.69) | ALBSMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL6349310 | 0.73 | ALB (0.83) | ALBMEN1KMT2ATP53ALDH1A1 | |
| SCHEMBL6932502 | 0.73 | ALB (0.54) | ALBMEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL6352010 | 0.73 | ALB (0.81) | ALBMEN1KMT2ATP53ALDH1A1 | |
| SCHEMBL6930797 | 0.72 | ALB (0.53) | ALBMEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL6830645 | 0.72 | ALB (0.48) | ALB | |
| SCHEMBL6357952 | 0.72 | ALB (0.83) | ALBMEN1KMT2ATP53ALDH1A1 | |
| SCHEMBL6830490 | 0.71 | HIF1A (0.55) | ALB | |
| SCHEMBL6359330 | 0.71 | TP53 (0.72) | ALBMEN1KMT2ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ALB 1417/4885MEN1 4132/4885KMT2A 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.